Autolus Therapeutics plc (AUTL) SEC Filings & Earnings Calls

Dependence on AUCATZYL for near-term revenue; pipeline still early stage.

“Revenue concentrated in AUCATZYL; pipeline trials in lupus, MS, pediatric ALL not yet pivotal.”

Credit facility may increase leverage risk.

“Five-year, interest-only credit facility of up to $250 million.” · word for word

Cash burn and need for additional financing

“We expect to incur significant expenses and operating losses for the foreseeable future as we market AUCATZYL and advance our other product candidates.” · word for word

Dependence on single product AUCATZYL

“We have one product approved for commercial sale in the United States and United Kingdom, AUCATZYL.” · word for word

Regulatory and commercial uncertainty in EU

“Evaluation of potential pricing and the feasibility of market entry opportunities in certain EU countries is ongoing; consequently, the commercial launch in Germany is currently on hold.” · word for word

Debt servicing costs; interest rate SOFR + 7.25%.

“Credit Facility will bear interest at a rate per annum equal to SOFR (subject to a SOFR floor of 3.50%), plus 7.25%.”

Dependence on AUCATZYL for revenue; clinical and regulatory risks for pipeline.

“Forward-looking statements about clinical trials and regulatory approvals.”

Dependence on AUCATZYL commercial success; pipeline setbacks could impact valuation.

“Revenue concentrated in single product; clinical trial risks for pipeline candidates.”

Restructuring execution risk; workforce reduction may impact morale and operations.

“Workforce reduction of 13% and restructuring charges of $8M.”

Cash burn and need for additional capital

“We will need significant additional capital to fund our operations until such time as we can generate significant revenue from sales of AUCATZYL or other products.” · word for word

Commercial execution risk for AUCATZYL

“Cost of sales increased by $6.6 million to $24.6 million for the three months ended March 31, 2026 from $18.0 million for the three months ended March 31, 2025.” · word for word

Clinical trial failure risk for pipeline

“We may never succeed in achieving regulatory approval for any of our product candidates other than AUCATZYL.” · word for word

Single product dependency; AUCATZYL is only approved product.

“All revenue from AUCATZYL; pipeline products in early stages.”

Manufacturing scale-up and cost reduction execution risk.

“Manufacturing life cycle plan to reduce costs; gross margin inflection expected in 2026.”

Competitive CAR-T market; potential pricing and reimbursement pressure.

“Market leading position in adult r/r B-ALL; competition from other CAR-T therapies.”

EU launch delay

“Evaluation of potential pricing and feasibility of market entry opportunities in certain European Union (EU) countries is ongoing; however, at this time, launch in the EU is on hold and we do not anticipate any EU sales of AUCATZYL in 2026.” · word for word

Significant operating losses

“We have incurred losses of $287.5 million and $220.7 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $1,386.8 million.”

Dependence on single product for near-term revenue

“Our product revenues in the near term will be derived primarily from sales of AUCATZYL in the US.” · word for word

BioNTech option non-exercise

“The product option for AUTO1/22 was not exercised and has expired as of 8 February 2025.” · word for word

MCSA option non-exercise

“On 6 August 2025, the MCSA option expired unexercised.” · word for word

Temporary lag in Q3 sales due to CMS reimbursement policy change.

“Expected temporary lag in Q3 sales based on change in CMS reimbursement policy.”

Dependence on clinical trial outcomes for pipeline expansion.

“Pipeline expansion depends on ongoing clinical trials in pediatric ALL and lupus nephritis.”

Commercialization execution risk

“Cost of sales exceeds product revenue; gross margin negative; EU launch on hold; UK reimbursement discussions ongoing.”

Dependence on AUCATZYL for revenue

“We have one product, AUCATZYL, approved for commercial sale in the United States, United Kingdom, and the EU.” · word for word

Significant operating losses and accumulated deficit

“We have an accumulated deficit of $1,296.4 million as of September 30, 2025.” · word for word

Need for additional capital

“We will need significant additional capital to fund our operations until such time as we can generate significant revenue from sales of AUCATZYL or other products.” · word for word

EU commercial launch delay

“Launch in Germany is on hold and we do not anticipate any EU sales of AUCATZYL in 2025 and 2026.” · word for word